{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:11:20Z","timestamp":1760116280090,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Aurora (AK) A\/B are oncogenic mitotic kinases that when over-expressed are poor prognostic markers in mantle cell lymphoma (MCL). Methods and Results: Alisertib, an AK-A inhibitor, has anti-tumor activity in relapsed\/refractory (r\/r) MCL patients. We evaluated alisertib plus ibrutinib in MCL to abrogate ibrutinib resistance. Alisertib plus ibrutinib was therapeutically synergistic on both Granta-519 insensitive to ibrutinib and JeKo-1 cells sensitive to ibrutinib. Alisertib decreased PI-3K, BTK, p38, HCK, and RSK kinases, indicative of its multipotent effect on cellular proliferation and growth. A mouse xenograft model of Granta-519 demonstrated that alisertib plus ibrutinib had a comparable anti-tumor response to ibrutinib plus rituximab. However, alisertib plus ibrutinib plus rituximab demonstrated significantly stronger tumor growth inhibition than the doublets. Conclusions: Both double and triple combinations showed enhanced survival versus ibrutinib alone. Ibrutinib insensitivity can be disrupted by alisertib plus ibrutinib in MCL.<\/jats:p>","DOI":"10.3390\/cancers16244257","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T09:13:38Z","timestamp":1734945218000},"page":"4257","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-3484","authenticated-orcid":false,"given":"Baskaran","family":"Subramani","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-5834","authenticated-orcid":false,"given":"Patrick J.","family":"Conway","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Graduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-1845","authenticated-orcid":false,"given":"Aisha","family":"Al-Khinji","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Clinical Translational Science Program, University of Arizona, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daruka","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Graduate School of Biomedical Sciences, University of Texas Health San Antonio, San Antonio, TX 78229, USA"},{"name":"Clinical Translational Science Program, University of Arizona, Tucson, AZ 85721, USA"},{"name":"Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2010.33.7055","article-title":"Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation","volume":"29","author":"Budde","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Jain, N., Havranek, O., Singh, R.K., Khashab, T., Shirazi, F., Sehgal, L., and Samaniego, F. (2019). Overcoming ibrutinib resistance by targeting phosphatidylinositol-3-kinase signaling in diffuse large B-cell lymphoma. BioRXIV.","DOI":"10.1101\/523761"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-Cell malignancies: Their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.15411","article-title":"Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"182","author":"Jain","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/genetics\/135.3.677","article-title":"Isolation and characterization of chromosome-gain and increase-in-polyploidy mutants in yeast","volume":"135","author":"Chan","year":"1993","journal-title":"Genetics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1242\/jcs.013136","article-title":"Aurora-A: The aker and breaker of spindle poles","volume":"120","author":"Barr","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of aurora kinases","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc1526","article-title":"Aurora-A\u2014A guardian of poles","volume":"5","author":"Marumoto","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4161\/cc.7.22.7042","article-title":"AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma","volume":"7","author":"Veerakumarasivam","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ceb.2007.11.008","article-title":"Polo and aurora kinases: Lessons derived from chemical biology","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr. Opin. Cell. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bcp.2011.01.017","article-title":"Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma","volume":"81","author":"Qi","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","article-title":"Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment","volume":"37","author":"Qi","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/1060028020909117","article-title":"Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents","volume":"54","author":"Buege","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_32","first-page":"845","article-title":"Alisertib induces G2\/M arrest, apoptosis, and autophagy via PI3K\/Akt\/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells","volume":"9","author":"Liu","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jim.2010.09.021","article-title":"Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition","volume":"363","author":"Estevam","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.3324\/haematol.2018.212811","article-title":"A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines","volume":"104","author":"Zucchetto","year":"2019","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-16-2703","article-title":"B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/leu.2016.129","article-title":"Decrease in total protein level of Bruton\u2019s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes","volume":"30","author":"Bose","year":"2016","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","article-title":"Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma","volume":"18","author":"Mahadevan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Mahadevan, D., Stejskal, A., Cooke, L.S., Manziello, A., Morales, C., Persky, D.O., Fisher, R.I., Miller, T.P., and Qi, W. (2014). Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095184"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-18-0286","article-title":"Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab\/Vincristine in Relapsed\/Refractory Aggressive B-cell Lymphoma","volume":"24","author":"Kelly","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IkappaB","volume":"17","author":"Ming","year":"2018","journal-title":"Mol. Cancer Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:30Z","timestamp":1760115450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":40,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244257"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244257","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,12,21]]}}}